Risdiplam is a small molecule that was recently approved for the treatment of pediatric and adult SMA patients by the FDA; EMA indications are restricted to patients 2 months of age and older, with a clinical diagnosis of SMA and one to four SMN2 copies. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.